AR069436A1 - Compuestos de piridina - Google Patents

Compuestos de piridina

Info

Publication number
AR069436A1
AR069436A1 ARP080105162A ARP080105162A AR069436A1 AR 069436 A1 AR069436 A1 AR 069436A1 AR P080105162 A ARP080105162 A AR P080105162A AR P080105162 A ARP080105162 A AR P080105162A AR 069436 A1 AR069436 A1 AR 069436A1
Authority
AR
Argentina
Prior art keywords
cor8
ring
cyano
nitro
halogen
Prior art date
Application number
ARP080105162A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR069436A1 publication Critical patent/AR069436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Proceso de preparacion, composicion farmacéutica y uso para tratar la diabetes, así como las sales y los ésteres farmacéuticamente aceptables de los mismos. Reivindicacion 1: Compuestos de la formula (1) en la que R1 (i) es un anillo fenilo, tiofenilo, furilo o pirrolilo benzo-condensado, dicho anillo benzo-condensado está opcionalmente sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, halogeno, -COR8, -R9-COR8, ciano, -R9-ciano, nitro y un anillo hidrocarburo mono- o policíclico, saturado y/o insaturado de hasta 10 átomos en el anillo, que puede tener hasta 4 heteroátomos elegidos entre N, S y O, que está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre halogeno, -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, -COR8, -R9-COR8, ciano y nitro, (ii) un anillo fenilo que está sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, halogeno, -COR8, -R9-COR8, ciano, -R9-ciano, nitro y un anillo hidrocarburo mono- o policíclico, saturado y/o insaturado de hasta 10 átomos en el anillo, que puede tener hasta 4 heteroátomos elegidos entre N, S y O, que está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre halogeno, -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, -COR8, -R9-COR8, ciano y nitro, o condensado con un anillo saturado de 5 o 6 eslabones, que puede tener hasta 3 heteroátomos elegidos entre N, S y O; dicho anillo condensado está opcionalmente de una a tres veces por sustituyentes elegidos con independencia entre -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, halogeno, -COR8, -R9-COR8, ciano, -R9-ciano, nitro y un anillo hidrocarburo mono- o policíclico, saturado, mono- o poliinsaturado de hasta 10 átomos en el anillo, que puede tener hasta 4 heteroátomos elegidos entre N, S y/o O, que está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre halogeno, -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, -COR8, -R9-COR8, ciano y nitro, con la condicion de que en la posicion 3 y/o 4 del anillo fenilo haya por lo menos un sustituyente diferente de hidrogeno, en el que el átomo de union del anillo fenilo se define como posicion 1, con la condicion adicional de que cuando el sustituyente de la posicion 4 del anillo fenilo es metilo, -O-metilo, -CO-metilo cloro o fluor; y el sustituyente de la posicion 3 del anillo fenilo es hidrogeno, entonces el sustituyente R3 del anillo piridina sea bromo o cloro, (iii) un anillo tiofenilo que está sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, halogeno, -COR8, -R9-COR8, ciano, -R9-ciano, nitro y un anillo hidrocarburo mono- o policíclico, saturado y/o insaturado de hasta 10 átomos en el anillo, que puede tener hasta 4 heteroátomos elegidos entre N, S y O, que está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre halogeno, -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, -COR8, -R9-COR8, ciano o nitro, con la condicion de que haya por lo menos un sustituyente diferente de hidrogeno, haloalquilo C2-3 y haloalquenilo C2-3; (iv) un anillo furilo que está sustituido de una a cuatro veces por sustituyentes elegidos con independencia entre -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, halogeno, -COR8, -R9-COR8, ciano, -R9-ciano, nitro y un anillo hidrocarburo mono- o policíclico, saturado y/o insaturado de hasta 10 átomos en el anillo, que puede tener hasta 4 heteroátomos elegidos entre N, S y O, que está opcionalmente sustituido de una a tres veces por sustituyentes elegidos con independencia entre halogeno, -R8, -O-R8, -R9-O-R8, -S-R8, -R9-S-R8, -COR8, -R9-COR8, ciano y nitro; R2 y R4 se eligen con independencia entre halogeno, ciano, nitro, hidroxi, -R8, -O-R8, -S-R8, -N(R8)2, -SO-R8, -SO2-R8, -CO-R8, -CO2-R8, -O-COR8, -CON(R8)2, -NR8-COR8, -NR8-COOR8, -R9-O-R8, -R9-S-R8, -R9-N(R8)2, -R9-SO-R8, -R9-SO2-R8, -R9-COR8, -R9-CO2-R8, -R9-O-CO-R8, -R9-CO(NR8)2, -R9-NR8-COR8, -NR6-CO-N(R8)2, -NR6-CO-N(R6)-SO2-R8, -NR6-CS-N(R8)2, -NR6-CS-SO2-R8 y -CN(R8)2=NOH; R3 y R5 son con independencia hidrogeno; R6 y R7 se eligen con independencia entre hidrogeno, alquilo, haloalquilo, hidroxialquilo y -R9-O-CO-R8; R8 se elige en cada caso con independencia entre hidrogeno y un resto orgánico saturado, mono- o poliinsaturado, acíclico o cíclico de hasta 20 átomos de carbono, que puede tener hasta 5 heteroátomos elegidos entre N, S y/o O, que puede estar sustituido por halogeno, ciano, nitro, hidroxi, amino, alcoxi, haloalcoxi, carboxiamida y carboxi-éster; y R9 se elige entre alquileno, arileno, aralquileno y alcarileno; y las sales y ésteres farmacéuticamente aceptables de los mismos.
ARP080105162A 2007-11-30 2008-11-27 Compuestos de piridina AR069436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122017 2007-11-30

Publications (1)

Publication Number Publication Date
AR069436A1 true AR069436A1 (es) 2010-01-20

Family

ID=40676394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105162A AR069436A1 (es) 2007-11-30 2008-11-27 Compuestos de piridina

Country Status (15)

Country Link
US (1) US8163778B2 (es)
EP (1) EP2227452A2 (es)
JP (1) JP2011504898A (es)
KR (1) KR20100072098A (es)
CN (1) CN102026978A (es)
AR (1) AR069436A1 (es)
AU (1) AU2008328956A1 (es)
BR (1) BRPI0820203A2 (es)
CA (1) CA2706576A1 (es)
CL (1) CL2008003546A1 (es)
IL (1) IL205666A0 (es)
MX (1) MX2010005714A (es)
PE (1) PE20091426A1 (es)
TW (1) TW200922574A (es)
WO (1) WO2009068468A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5689321B2 (ja) * 2010-01-21 2015-03-25 石原産業株式会社 ２−アミノ−４−トリフルオロメチルピリジン類の製造方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014029722A1 (en) 2012-08-21 2014-02-27 F. Hoffmann-La Roche Ag Novel pyridine derivatives
CN104496895B (zh) * 2014-12-18 2017-02-01 天津汉德威药业有限公司 一种水解制备异烟酸的方法
CN113527194B (zh) * 2021-03-15 2023-10-03 武威广达科技有限公司 一种2-氨基-3-氯-5-三氟甲基吡啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD9688A (es) *
US2977375A (en) * 1953-02-11 1961-03-28 Boehringer & Soehne Gmbh Process of manufacturing n-sulphanilyl ureas
GB797474A (en) * 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
DE1011413B (de) * 1955-11-28 1957-07-04 Boehringer & Soehne Gmbh Verfahren zur Herstellung von oral wirksamen Antidiabetika
US4293330A (en) * 1979-10-09 1981-10-06 E. I. Du Pont De Nemours And Company Herbicidal N-(pyridinylaminocarbonyl)benzenesulfonamides
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
AUPN193095A0 (en) * 1995-03-24 1995-04-27 Polychip Pharmaceuticals Pty Ltd Potassium ion channel blockers
US6693123B2 (en) * 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6965033B2 (en) * 1999-12-22 2005-11-15 Metabasis Therapeutics, Inc. Bisamidate phosphonate prodrugs
AU2003252676A1 (en) 2002-07-23 2004-02-09 Sankyo Company, Limited Preventive for the onset of diabetes
FR2889190A1 (fr) * 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
DK200600313A (da) * 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor

Also Published As

Publication number Publication date
CA2706576A1 (en) 2009-06-04
CN102026978A (zh) 2011-04-20
JP2011504898A (ja) 2011-02-17
AU2008328956A1 (en) 2009-06-04
US20090143439A1 (en) 2009-06-04
WO2009068468A3 (en) 2010-04-22
WO2009068468A2 (en) 2009-06-04
IL205666A0 (en) 2010-11-30
MX2010005714A (es) 2010-07-01
BRPI0820203A2 (pt) 2015-06-16
TW200922574A (en) 2009-06-01
PE20091426A1 (es) 2009-09-23
US8163778B2 (en) 2012-04-24
EP2227452A2 (en) 2010-09-15
KR20100072098A (ko) 2010-06-29
CL2008003546A1 (es) 2010-02-05

Similar Documents

Publication Publication Date Title
AR069436A1 (es) Compuestos de piridina
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
ES2515194T3 (es) Derivados de pirrolidina
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR070479A1 (es) Derivado heterociclico fusionado y su uso
PA8783601A1 (es) Derivados de piperidina/piperazina
CO6180440A2 (es) Compuestos y composiciones como inhibidores de proteinquinasas
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
AR084032A1 (es) Compuesto biciclico
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR080802A1 (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure